Thank you for subscribing!

Revolutionary Technology That’s Changing the Face of Transdermal Skincare

How NEXGEL is Pioneering Skin-Friendly Patches

  • Rapid Revenue Growth – First quarter 2022 revenue increased 48% YoY to $396k.
  • History Typically Repeats Itself – As a company that’s historically experienced growth month over month, Nexgel is in a position to potentially yield more of the same.
  • Opportunity Abounds – The custom label business represents a significant commercialization opportunity for Nexgel going forward, while it continues to gain traction from the e-commerce proprietary consumer health brand, Medagel. Both avenues represent significant opportunities for growth.

 

Skincare may not seem like an exciting investment until you meet the company that’s rapidly changing the way the world thinks about transdermal medication delivery.

Meet NEXGEL. Touting themselves as “your skin-friendly patch company”, NEXGEL is using their own proprietary hydrogel technology to create one-of-a-kind skin patches to suit a whole host of needs.

As an experienced medical device manufacturer, NEXGEL is not new to the game, but they are bringing new technology to consumer products for the first time. They’re filling a niche that’s never been accommodated before, and it’s working. Month over month, they continue to profit, grow, and develop new products, making NEXGEL an investment opportunity that is beyond appealing.

 

Flawless and Groundbreaking

The First of Their Kind

A pioneer in skincare, NEXGEL has recognized a need for a different type of transdermal delivery system – one that was highly effective while remaining gentle enough to be used on any type of skin. This drive led them to develop the hydrogel technology they’re still using today. Free from harmful chemicals and adhesives, NEXGEL’s patches have been implemented by major players in both the medical and skin care industries, and more companies are jumping on board every day.

A Unique Process

Hydrogels are gel-like or colloidal substances created by combining water with various solids. There are plenty of companies that use hydrogels, but most create theirs via chemical cross-linking. NEXGEL implements electron beam cross-linking to create a product that’s gentle and can be easily combined with medical and/or cosmetic active ingredients. It’s also a process that makes it easier to incorporate “green” and vegan products into the mix. It’s this innovative approach to hydrogel creation that makes NEXGEL’s products so appealing to companies, investors, and consumers alike.

Exponential Growth

All you have to do is look at NEXGEL’s financial results to see why they’re crushing the industry. Their first-quarter revenue for 2021 came in at approximately $267,000 and in just three months, that grew into a second-quarter revenue of $417,000. Revenue increased to $396,000 in Q1 2022, a 48% jump compared to Q1 the previous year. The company reported those revenue increases came from sales growth of new products and initiatives in branded consumer products.

A Team of Experts

While passion certainly drives this company, it’s also being propelled to greatness by a team of industry experts who aren’t shy about breaking the mold. From a CEO with over 34 years in capital markets and direct-to-consumer sales to a scientific advisory board packed with medical professionals spanning a wide range of specialties, NEXGEL has the resources to continue developing high-quality, effective products.

Rapid Expansion

In the years since NEXGEL’s inception, they’ve developed an impressive 200+ unique formulations with a combination of OTC, cosmetic, and natural ingredients. This repertoire has caught the eye of many in the medical and cosmetic fields, as well as consumers. In fact, their success during the second quarter of 2021 is due, in large part, to new customer orders for custom label products. These whitelabeling efforts, combined with the recent launch of their direct-to-consumer sales campaigns bode well for NEXGEL’s financial future.

Road to Innovation 

We live in a world where most people are becoming increasingly concerned about what they put in and on their bodies. Sure, they want to use products that are efficient and effective, but they also want them to come along with labels like “all-natural”, “organic”, and “safe”. It’s important to a lot of people, and it’s no wonder why given that it seems like nearly everything we eat, drink, or use is, in some way, not good for us.

Consumers, cosmetology professionals, and medical professionals alike would complain that the existing patches were too uncomfortable, too sticky, too itchy, and so on and so forth. They dried out the skin and left red, splotchy irritation in their wake. Not to mention that many of these products were filled with all kinds of additives and chemicals. They just… weren’t great.

Enter NEXGEL. They decided that they would be the great skin patch company that the world deserved. And, so far, they are.

Now, NEXGEL is manufacturing new products at an astonishing rate. Their innovation has gone a long way toward their success and has been instrumental in developing their proprietary hydrogel technology. It’s allowed them to develop a process for creating skin patches that don’t come paired with a bunch of needless ingredients. In fact, NEXGEL doesn’t use chemical cross-linking agents or chemical adhesives at all.

Instead, NEXGEL uses an electron-beam cross-linking process to set their gels into a solid, usable form. And, because they can add additional ingredients at any point throughout this process, this futuristic technology makes NEXGEL’s products highly flexible and customizable.

NEXGEL Reports First Quarter 2022 Financial Results

First quarter 2022 revenue increased 48% YoY to $396 Thousand

Company launched two new consumer OTC products using its HYDROGEL Technology: The MEDAGEL ClearComfort Hydrogel Patch and The MEDAGEL Bug Bite Relief Patch

LANGHORNE, Pa., May 12, 2022 /PRNewswire/ — NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced its financial results for the first quarter ended March 31, 2022.

Adam Levy, NEXGEL Chief Executive Officer, commented, “We are pleased with our financial results for the quarter. We have remained focused on our growth strategy within each of our core business segments – branded products, contract manufacturing, and medical devices. Our consumer segment had a strong start to the year with the launch of two new OTC products, The MEDAGEL ClearComfort Hydrogel Patch and The MEDAGEL Bug Bite Relief Patch. MEDAGEL now has 10 SKUs available on Amazon, and the products continue to be a steady contributor to our revenue growth. In our contract manufacturing segment, we are making progress on growing the business through our new offering that allows OTC brands to leverage our hydrogel products for line extensions for their products. We are making progress with this strategy and are focused on expanding the business. Lastly, we remain committed our medical device segment and continue to make advancements on our first product, NEXDrape, which is in the research and development phase. We expect our revenue growth year-over-year trend to continue for the foreseeable future.”

First Quarter 2022 Financial Highlights

Revenue for the three months ended March 31, 2022, was $396 thousand, an increase of $129 thousand, or 48%, when compared to $267 thousand for the three months ended March 31, 2021. The increase in our overall revenue was due to sales growth of new products as well as our initiatives in branded consumer products.

Gross loss for the first quarter of 2022 was $22 thousand, compared to a gross loss of $42 thousand for the three months ended March 31, 2021.

Cost of revenues increased by $109 thousand, or 35%, to $418 thousand for the three months ended March 31, 2022, as compared to $309 thousand for the three months ended March 31, 2021. The increase in cost of revenues is primarily aligned with the new product line growth in the current year.

Operating expenses, including research and development and selling, general and administrative expenses, increased by $312 thousand to $790 thousand for the three months ended March 31, 2022, as compared to $478 thousand for the three months ended March 31, 2021. The increase in Selling, general and administrative expenses is primarily attributable to costs for professional fees and other administrative expenses in the current period associated with public company governance requirements.

Cash and cash equivalents as of March 31, 2022 was $10.50 million as compared to $13.4 million as of December 31, 2021, primarily due to the Company’s principle payments of notes payable in the amount of approximately $2 million.

First Quarter 2022 Operational Highlights

Launched MEDAGEL ClearComfort Hydrogel Patch. MEDAGEL patches use NEXGEL’s advanced hydrogel technology to prevent and treat foot blisters by comfortably insulating the skin from friction caused by rubbing and chafing in shoes. They are available in a variety of shapes, including a customizable sheet that allows consumers to cut and create a perfect fit for their specific shoe needs. The product is available for sale on Amazon.com.

Launched MEDAGEL Bug Bite Relief Patch. Made in the USA, the MEDAGEL Bug Bite Relief Patches are skin-friendly and infused with skin-calming Arnica flower and pain-reducing Lidocaine to help reduce discomfort. The product is available for sale on Amazon.com.

Something For Everyone

Because just about anything can be added to the hydrogels, medicated or otherwise, NEXGEL’s products have proven to be appealing to professionals in a wide range of industries. They’ve worked with major companies, we’re talking Fortune 500 level companies, to create specialized drug delivery patches.

They’ve worked with startups to create cosmetic solutions that are gentle and safe for any type of skin. And now, they’re starting to offer their products directly to the consumer. That’s right. As of late, consumers can find certain NEXGEL products, like Fever Cool and Nip Defense, on Amazon. Consumers can also purchase products like Hexagel, a deionized water and aloe patch designed to soothe irritation, and SilverSeal®, a hydrogel dressing for minor burns and wounds.

They’re also breaking into the field of custom products and are offering more and more whitelabel solutions to private brands, allowing businesses to help formulate their own products and rebrand under their own company name. These “designer formulations”, if you will, have and surely will continue to boost NEXGEL’s bottom line.

Prime Products

In addition to the custom solutions that NEXGEL is working to provide various companies, they also have a range of products that have become staples throughout their time in business.

Take their facemask for example. If you’ve ever worn a facemask, you know there are good ones and bad ones. The bad ones are made of wet, unpleasant cloth that slips off your face, makes your skin tingle (not in a good way), and produces strong odors that burn your eyes. The good ones, well, they do none of those things.

NEXGEL’s facemasks stay where they’re placed, and they don’t incorporate chemicals that can irritate the skin. They’re made of 90%+ water, and feature soothing ingredients like aloe vera and hyaluronic acid that leave consumers with skin that feels fresh, cool, and hydrated.

Okay, so you may not have a need for facemasks, but we’re betting that you’ve had at least one blister in your lifetime. NEXGEL’s Hexagel patches not only provides a barrier between your skin and shoes that rub a little too much, but they can help heal blisters if the damage has already been done. They stay on for 12 hours, are low profile, and are so comfortable you won’t even know they are there. When you take them off, you’ll find skin that’s ultra-hydrated and free of sticky residue, making it a truly dynamic product.

Then there are OTC products to consider, like NEXGEL’s Fever Cool. Designed to deliver fever-reducing OTC medications right to where they’re needed, these patches also help cool and soothe hot skin. No fever? No problem. Fever Cool is also a great choice for those who suffer from headaches or migraines which, let’s face it, is most of us.

There’s also SilverSeal. This hydrogel dressing harnesses the natural power of silver to soothe burns and prompt scar reduction. It’s also a great choice for helping to heal minor superficial wounds, minor lacerations, and even minor abrasions, and has been used in hospital settings for over a decade.

It’s Time to Invest

As a company that’s historically experienced exponential growth month over month, investing should be a no-brainer. After all,

NEXGEL is one of only three electron-beam hydrogel facilities in the United States,

so calling them unique or special would be somewhat of an understatement.

Not only that, but they truly do offer something for everyone. Whether you’re a working parent with a sick kid, an elderly individual looking for products that won’t tear your skin, a cosmetologist searching for the best skincare products to share with your clients, or a Fortune 500 company that needs a partner for transdermal drug delivery patches, NEXGEL really does have something for you.

Fortunately for investors looking to spice up their portfolios, NEXGEL is about to enter the market, and they’re looking forward to shaking things up.

NEXGEL CEO Adam Levy shared some of the company’s upcoming plans with a hearty dose of optimism and assuredness, “It is great to see that our new product offerings are being met with excitement from the market. We have partnered with some of the industry’s leading beauty and consumer health companies to develop fully customizable products that leverage our ultra-gentle, high-water-content hydrogels. Our custom label business represents a significant commercialization opportunity going forward, while we continue to gain traction from our e-commerce proprietary consumer health brand, Medagel, with plans to launch our beauty & cosmetics brand, Lumagel, in the Fall of 2021.”

Whether you want to learn more or simply want to keep tabs on NEXGEL’s future, you can find everything you need to know at NEXGEL.com.

 

PR and News

 

Management

Adam Levy

CEO

34 years of expertise in capital markets, consumer products, marketing, television/radio advertising, and direct-to-consumer sales. Led the successful turnaround of several financially distressed music companies as CEO of Warlock Records.

Gregory J. Robb

VP, Operations

Greg has 30 years of experience in the electron beam processing industry backing him. He has spent the last 23 years producing electron beam cross-linked hydrogels. Mr. Robb designed the layout, coordinated, and supervised the construction of the NEXGEL facility.

Kelly Knobeck

Director of Consumer Products

6+ years of management, product coordinating, and project planning experience. Creative lead and manager of all marketing efforts.

Jason Cattell

Production Supervisor

Manjari Valia

Quality Assurance Manager

May Dechaphaithunsuk

Production Assistant

Daphnee Elysee

Sr. Chemist & Manufacturing Supervisor

 

Scientific Advisory Board

Dr. Stephen Brigido

Dr. Brigido is an accomplished surgeon and entrepreneur with seventeen years of experience in foot and ankle surgery, regenerative medicine, and product development. In his role as a foot and ankle surgeon, Dr. Brigido has served as Chief of the Foot and Ankle Section at Coordinated Health for ten years and has been the Director of the prestigious Reconstructive Foot and Ankle Fellowship for 9 years; with each of his fellows moving on to some of the most revered institutions in the country. In 2013, Dr. Brigido was named Professor of Surgery at the Geisinger Commonwealth Medical College and has over 100 peer-reviewed publications and book chapters in his name. He’s been featured on numerous media outlets for his research in biomaterials and regenerative scaffolds as well as Total Ankle replacement surgery. In 2019, Dr. Brigido was named President of the Functional Regeneration Division at Celularity, a multi-platform cell therapy company in Warren, NJ.

In addition to his role at Celularity, Dr. Brigido serves on the Board of Directors of Plazmology4, is a managing partner and founder at Venel Holdings LLC, and partner in BBHP Medical LLC, a healthcare incubator company. Dr. Brigido has commercialized over 40 orthopedic implants and biomaterials and has numerous patents in the field of orthopedics and regenerative medicine. He received his Bachelor of Science from Randolph-Macon College and his Doctor of Podiatric Medicine from Temple University.

Dr. Jerome Zeldis Chair

Dr. Jerome B. Zeldis was Chief Medical Officer and President of Clinical Research, Regulatory, and Safety at Sorrento Therapeutics. He was Chief Executive Officer of Celgene Global Health and Chief Medical Officer of Celgene Corporation. Prior to that he was Celgene’s Senior Vice President of Clinical Research and Medical Affairs and had been at Celgene since February 1997 before joining Sorrento. He attended Brown University for an A.B., M.S., followed by Yale University for an M.Phil., M.D., Ph.D. in Molecular Biophysics and Biochemistry (immunochemistry).

Dr. Zeldis trained in Internal Medicine at the UCLA Center for the Health Sciences and Gastroenterology at the Massachusetts General Hospital and Harvard Medical School. He has been a board member of several start-up biotechnology companies and is currently on the board of the PTC Corporation (PTCT), Soligenix, Trek Therapeutics, and Bionor Pharma. He has published 122 peer-reviewed articles and created 43 US patents.

Dr. Steven Banco

Stephen P. Banco, MD is a board-certified, fellowship-trained Orthopaedic Spinal Surgeon. Dr. Banco received his undergraduate degree from Lehigh University. He attended Jefferson Medical College and completed his residency at Thomas Jefferson University Hospital and The Rothman Institute. Dr. Banco completed a spinal surgery fellowship at The New England Baptist Hospital in Boston

Dr. Banco is currently on the Editorial Review Board of Clinical Spine Surgery and has recently authored two book chapters in The Spine.  He has published original research articles in The Journal of Bone and Joint Surgery, Spine and Current Opinions in Orthopedics.

Dr. Banco is the President of Keystone Spine and Pain Management Center. He is President-Emeritus and a founding member of Keystone Orthopedic Specialists and maintains active privileges at The Surgical Institute of Reading and Penn State Health/St Joseph’s.  Dr. Banco has been a practicing orthopedic spinal surgeon for 14 years.

 

DISCLAIMER

Who are we and what do we do? We are paid advertisers, also known as stock touts or stock promoters, who disseminate favorable information (the “Information”) about publicly traded companies (the “Profiled Issuers”). How is the Information published? We publish the Information on our Website, in newsletters, audio services, live interviews, featured “research” reports, on message boards and in email communications for specific time periods that are agreed upon between us and the Profiled Issuer or third party paying us. Our publication of the Information is known as a “Campaign”. Will everyone receive the Information at the same time? No. The Information may be sent to potential investors at different times that are minutes, hours, days or even weeks apart. How is a potential investor impacted if he/she receives the Information later than other investors? Typically, the trading volume and price of a Profiled Issuer’s securities increases after the Information is provided to the first group of investors. Therefore, the later an investor receives the Information, the more likely it is that he/she may suffer increased trading losses if he/she purchases the securities of a Profiled Issuer. What will happen when the Campaign ends? Most, if not all, of the Profiled Issuers are penny stocks that are illiquid and whose securities are subject to wide fluctuations in trading price and volume. During the Campaign the trading volume and price of the securities of each Profiled Issuer will likely increase significantly. When the Campaign ends, the volume and price of the Profiled Issuer will likely decrease dramatically. As a result, investors who purchase during the Campaign and hold shares of the Profiled Issuer when the Campaign ends will probably lose most, if not all, of their investment. Why do we publish only favorable Information? We only publish favorable information because we are compensated to publish only favorable information. Why don’t we publish negative Information? We don’t publish negative information because we are not paid to publish negative information. We are paid to publish only favorable information. Is the Information complete, accurate, truthful or reliable? No. The Information is a snapshot that provides only positive information about the Profiled Issuers. The Information consists of only positive content. We do not and will not publish any negative information about the Profiled Issuers; accordingly, investors should consider the Information to be one-sided and not balanced, complete, accurate, truthful or reliable. What we do not do? We do not publish negative information about the Profiled Issuers. We do not verify or confirm any portion of the Information. We do not conduct any due diligence, nor do we research any aspect of the Information including the completeness, accuracy, truthfulness or reliability of the Information. We do not review the Profiled Issuers’ financial condition, operations, business model, management or risks involved in the Profiled Issuer’s business or an investment in a Profiled Issuer’s securities. Where does the Information come from? The Information is provided to us by the Profiled Issuers and/or the person who hires us. We may also obtain the Information from publicly available sources such as the OTC Markets, Google, NASDAQ, NYSE, the Securities and Exchange Commission’s Edgar database or other available public sources. If we say we make “stock picks,” are those picks our own? No, they are not. We are compensated to advertise the securities we are told to advertise. What will happen if an investor relies on the Information? If an investor relies on the Information in making an investment decision it is highly probable that the investor will lose most, if not all, of his or her investment. Investors should not rely on the Information to make an investment decision. Who pays us to publish the Information? The source of our compensation varies depending upon the particular circumstances of the Campaign. We are compensated by the Profiled Issuers, third party shareholders and other parties related to the Profiled Issuers such as officers and/or directors who will derive a financial or other benefit from an increase in the trading price and/or volume of a Profiled Issuer’s securities. The nature and amount of compensation we receive for publishing the Information about each Profiled Issuer and our ownership of each Profiled Issuer is set forth below under the heading captioned, “What we are compensated”. What warranties do we make about the Information? None. We make no warranty or representation about the Information, including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable and as such, your use of the Information is at your own risk. The Information is provided as is without limitation. What we are not. We are not and do not act in the capacity of any of the following; as such, you should not construe our activities as involving any of the following:
  • An independent adviser or consultant;
  • A fortune teller;
  • An investment adviser or an entity engaging in activities that would be deemed to be providing investment advice that requires registration either at the federal or state level;
  • A broker-dealer or an individual acting in the capacity of a registered representative or broker;
  • A stock picker;
  • A securities trading expert;
  • A securities researcher or analyst;
  • A financial planner or one who engages in financial planning;
  • A provider of stock recommendations;
  • A provider of advice about buy, sell or hold recommendations as to specific securities; or
  • An agent offering or securities for sale or soliciting their purchase.
Are risks in this disclaimer the only risks investors should be aware of? No. There are numerous risks associated with each Profiled Issuer and investors should undertake a full review of each Profiled Issuer with the assistance of their financial, legal, and tax advisers prior to purchasing the securities of any Profiled Issuer. What conflicts of interest do we have in publishing the Information? We are not objective or independent and have multiple conflicts of interest. The Profiled Issuers and parties hiring us have conflicts of interest. Our publication of the Information involves actual and material conflicts of interest including but not limited to the following:
  • We receive monetary and/or securities compensation in exchange for publishing the (favorable) Information about the Profiled Issuers;
  • We do not publish any negative information whatsoever about the Profiled Issuers;
  • We may own a Profiled Issuer’s securities that we acquired from the Profiled Issuer, third parties or from our own open market purchases before, during or after the Campaign and we may sell these securities during the Campaign while publishing the (favorable) information that instructs investors to purchase. Our selling of a Profiled Issuer’s securities will likely cause investors to suffer losses;
  • A short time after we acquire a Profiled Issuer’s payment via cash or securities, we may publish the (favorable) Information about the Profiled Issuer advising others, including you, to purchase; and while doing so, we may sell the Profiled Issuer’s securities we acquired during our public dissemination of the Information causing us to profit while you suffer a loss;
  • Parties holding a Profiled Issuer’s securities, including those who engage our services and/or compensate us, will sell their shares of the Profiled Issuer while we are publishing the (favorable) Information.
Who is responsible if an investor relies on the Information? The investor. We are not responsible or liable for any person’s use of the Information or any success or failure that is directly or indirectly related to such person’s use of the Information because we have specifically stated that the information is not reliable and should not be relied upon for any purpose. We are not responsible for omissions or errors in the Information, and we are not responsible for actions taken by any person who relies upon the Information. What do we urge potential investors to do? We urge Investors to conduct their own in-depth investigation of the Profiled Issuers with the assistance of their legal, tax and investment advisers. An investor’s review of the Information should include but not be limited to the Profiled Issuer’s financial condition, operations, management, products or services, trends in the industry and risks that may be material to the profiled Issuer’s business and other information he and his advisers deem material to an investment decision. An investor’s review should include, but not be limited to a review of available public sources and information received directly from the Profiled Issuers or from websites such as Google, OTC Markets, NASDAQ, NYSE, www.sec.gov or other available public sources. Why is this Disclaimer being provided? We are providing you with this disclaimer because we are publishing advertisements about penny stocks. Because we are paid to disseminate the Information to the public about securities, we are required by the securities laws including Section 10(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 thereunder, and Section 17(b) of the Securities Act of 1933, as amended (the “Securities Act”), to specifically disclose our compensation as well as other important information, This information includes that we may hold, as well as purchase and sell, the securities of a Profiled Issuer before, during and after we publish favorable Information about the Profiled Issuer. We may urge investors to purchase the securities of a Profiled Issuer while we sell our own shares. The anti-fraud provisions of federal and state securities laws require us to inform you that we may engage in buying and selling of Profiled Issuer’s securities before, during and after the Campaigns. What are other risks that investors should be aware of? Any investment in the Profiled Issuers involves a high degree of risk and uncertainty. The securities may be subject to extreme volume and price volatility, especially during the Campaigns. Favorable past performance of a Profiled Issuer does not guarantee future results. If you purchase the securities of the Profiled Issuers, you should be prepared to lose your entire investment. Some of the risks involved in purchasing securities of the Profiled Issuers include, but are not limited to the risks stated below.
  • We do not endorse, independently verify or assert the truthfulness, completeness, accuracy or reliability of the Information. We conduct no due diligence or investigation whatsoever of the Information or the Profiled Issuers and we do not receive any verification from the Profiled Issuer regarding the Information we disseminate.
  • If we publish any percentage gain of a Profiled Issuer from the previous day close in the Information, it is not and should not be construed as an indication that the future stock price or future operational results will reflect gains or otherwise prove to be advantageous to your investment.
  • The Information may contain statements asserting that a Profiled Issuer’s stock price has increased over a certain period of time which may reflect an arbitrary period of time, and is not predictive or of any analytical quality; as such, you should not rely upon the (favorable) Information in your analysis of the present or future potential of a Profiled Issuer or its securities.
  • The Information should not be interpreted in any way, shape, form or manner whatsoever as an indication of the Profiled Issuer’s future stock price or future financial performance.
  • You may encounter difficulties determining what, if any, portions of the Information are material or non-material, making it all the more imperative that you conduct your own independent investigation of the Profiled Issuer and its securities with the assistance of your legal, tax and financial advisor.
  • We or other stock promoters may receive free trading shares as compensation or we may acquire such shares in open market transactions before and during the Campaigns, and we may sell the shares we acquire at any time, even during the Campaigns while publishing the Favorable Information. When we sell the shares of the Profiled Issuers that we hold, the price at which investors can sell their shares will dramatically decrease and will likely cause investors to suffer trading losses.
  • We may sell securities of the Profiled Issuers for less than target prices set forth in the Information, and we may profit by selling our securities during the Campaigns while investors encounter losses.
  • When we acquire, purchase or sell the securities of the Profiled Issuers, it may (a) cause significant volatility in the Profiled Issuer’s securities; (b) cause temporary but unrealistic increases in volume and price of the Profiled Issuer’s securities; (c) if selling, cause the Profiled Issuer’s stock price to decline dramatically; and (d) permit us to make substantial profits while investors who purchase during the Campaign experience significant losses.
  • The securities of the Profiled Issuers are high risk, unstable, unpredictable and illiquid which may make it difficult for investors to sell their securities of the Profiled Issuers.
  • If we are compensated in improperly free trading securities of the Profiled Issuers, either directly or indirectly from persons who claim to be non-affiliates of such Profiled Issuer, we and the Profiled Issuer or third party could be subject to SEC Enforcement Action, including allegations of an illegal distribution in violation of Section 5(a) and 5(c) of the Securities Act.
  • We may hire third party service providers and stock promoters to electronically disseminate live news regarding the Profiled Issuers, yet we have no control over the content of and do not verify the information that the Profiled Issuers and/or third party service providers publish. These third party service providers are likely compensated for providing positive information about the Issuer and fail to disclose their compensation to you.
If a Profiled Issuer is an SEC reporting company, it could be delinquent (not current) in its periodic reporting obligations (i.e., in its quarterly and annual reports), or if it is an OTC Markets Pink Sheet quoted company, it may be delinquent in its Pink Sheet reporting obligations, which may result in OTC Markets posting a negative legend pertaining to the Profiled Issuer at www.otcmarkets.com, as follows: (i) “Limited Information” for companies with financial reporting problems, economic distress, or that are unwilling to file required reports with the Pink Sheets; (ii) “No Information,” which characterizes companies that are unable or unwilling to provide any disclosure to the public markets, to the SEC or the Pink Sheets; and (iii) “Caveat Emptor,” signifying buyers should be aware that there is a public interest concern associated with a company’s illegal spam campaign, questionable stock promotion, known investigation of a company’s fraudulent activity or its insiders, regulatory suspensions or disruptive corporate actions. If the Information states that a Profiled Issuer’s securities are consistent with the future economic trends or even if your independent research indicates that, you should be aware that economic trends have their own limitations, including: (a) that economic trends or predictions may be speculative; (b) consumers, producers, investors, borrowers, lenders and government may react in unforeseen ways and be affected by behavioral biases that we are unable to predict; (c) human and social factors may outweigh future economic trends that we state may or will occur; (d) clear cut economic predictions have their limitations in that they do not account for the fundamental uncertainty in economic life, as well as ordinary life; (e) economic trends may be disrupted by sudden jumps, disruptions or other factors that are not accounted for in economic trends analysis; in other words, past or present data predicting future economic trends may become irrelevant in light of new circumstances and situations in which uncertainty becomes reality rather than predicted economic outcome; or (f) if the trend predicted involves a single result, it ignores other scenarios that may be crucial to make a decision in the event of unknown contingencies. The Information is presented only as a brief snapshot of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities. You should consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.govwww.sec.gov, www.otcmarkets.com or other electronic media, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the OTCMarkets.com; (c) obtaining and reviewing publicly available information contained in commonly known search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.org. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and the OTC Markets and/or have negative legends and designations at otcmarkets.com. What we were paid to advertise the Profiled Issuers. The details of our compensation and the period of the Campaign is set forth below.
  • Name of Issuer & Ticker Symbol - NEXGEL, Inc. (NXGL)
  • Amount & Form of Compensation - $108,000.00 in USD
  • Who Paid for the Campaign & Position with Company if any - NEXGEL, Inc. (NXGL)
  • Period of Campaign - 11/16/2021 - 2/16/2022

Related Post

Register to Download Presentation

Go to website
Go to top